XSpray Pharma (Sweden) Probability of Future Stock Price Finishing Over 84.24

XSPRAY Stock  SEK 42.15  0.15  0.36%   
XSpray Pharma's future price is the expected price of XSpray Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of XSpray Pharma AB performance during a given time horizon utilizing its historical volatility. Check out XSpray Pharma Backtesting, XSpray Pharma Valuation, XSpray Pharma Correlation, XSpray Pharma Hype Analysis, XSpray Pharma Volatility, XSpray Pharma History as well as XSpray Pharma Performance.
  
Please specify XSpray Pharma's target price for which you would like XSpray Pharma odds to be computed.

XSpray Pharma Target Price Odds to finish over 84.24

The tendency of XSpray Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over kr 84.24  or more in 90 days
 42.15 90 days 84.24 
near 1
Based on a normal probability distribution, the odds of XSpray Pharma to move over kr 84.24  or more in 90 days from now is near 1 (This XSpray Pharma AB probability density function shows the probability of XSpray Stock to fall within a particular range of prices over 90 days) . Probability of XSpray Pharma AB price to stay between its current price of kr 42.15  and kr 84.24  at the end of the 90-day period is about 83.75 .
Assuming the 90 days trading horizon XSpray Pharma AB has a beta of -0.64. This entails as returns on the benchmark increase, returns on holding XSpray Pharma are expected to decrease at a much lower rate. During a bear market, however, XSpray Pharma AB is likely to outperform the market. Additionally XSpray Pharma AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   XSpray Pharma Price Density   
       Price  

Predictive Modules for XSpray Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as XSpray Pharma AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
38.8042.1545.50
Details
Intrinsic
Valuation
LowRealHigh
36.0439.3942.74
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as XSpray Pharma. Your research has to be compared to or analyzed against XSpray Pharma's peers to derive any actionable benefits. When done correctly, XSpray Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in XSpray Pharma AB.

XSpray Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. XSpray Pharma is not an exception. The market had few large corrections towards the XSpray Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold XSpray Pharma AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of XSpray Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.14
β
Beta against Dow Jones-0.64
σ
Overall volatility
6.41
Ir
Information ratio -0.05

XSpray Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of XSpray Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for XSpray Pharma AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
XSpray Pharma AB generated a negative expected return over the last 90 days
XSpray Pharma AB has high historical volatility and very poor performance
XSpray Pharma AB has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (96.7 M) with profit before overhead, payroll, taxes, and interest of 656 K.
XSpray Pharma AB has accumulated about 192.85 M in cash with (51.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.79.
Roughly 47.0% of the company outstanding shares are owned by insiders

XSpray Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of XSpray Stock often depends not only on the future outlook of the current and potential XSpray Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. XSpray Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding19.2 M
Cash And Short Term Investments271.9 M

XSpray Pharma Technical Analysis

XSpray Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. XSpray Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of XSpray Pharma AB. In general, you should focus on analyzing XSpray Stock price patterns and their correlations with different microeconomic environments and drivers.

XSpray Pharma Predictive Forecast Models

XSpray Pharma's time-series forecasting models is one of many XSpray Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary XSpray Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about XSpray Pharma AB

Checking the ongoing alerts about XSpray Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for XSpray Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
XSpray Pharma AB generated a negative expected return over the last 90 days
XSpray Pharma AB has high historical volatility and very poor performance
XSpray Pharma AB has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (96.7 M) with profit before overhead, payroll, taxes, and interest of 656 K.
XSpray Pharma AB has accumulated about 192.85 M in cash with (51.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.79.
Roughly 47.0% of the company outstanding shares are owned by insiders

Other Information on Investing in XSpray Stock

XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.